Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in Newton, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-600-6888
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees57
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Stealth BioTherapeutics (NASDAQ:MITO) Frequently Asked Questions
What is Stealth BioTherapeutics' stock symbol?
Stealth BioTherapeutics trades on the NASDAQ under the ticker symbol "MITO."
How were Stealth BioTherapeutics' earnings last quarter?
Stealth BioTherapeutics Corp (NASDAQ:MITO) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.04) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.08) by $0.04. View Stealth BioTherapeutics' Earnings History.
When is Stealth BioTherapeutics' next earnings date?
What price target have analysts set for MITO?
6 analysts have issued twelve-month target prices for Stealth BioTherapeutics' stock. Their forecasts range from $16.00 to $35.00. On average, they anticipate Stealth BioTherapeutics' stock price to reach $25.17 in the next twelve months. This suggests a possible upside of 252.0% from the stock's current price. View Analyst Price Targets for Stealth BioTherapeutics.
What is the consensus analysts' recommendation for Stealth BioTherapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stealth BioTherapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stealth BioTherapeutics.
Has Stealth BioTherapeutics been receiving favorable news coverage?
Press coverage about MITO stock has been trending negative recently, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Stealth BioTherapeutics earned a coverage optimism score of -2.6 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Stealth BioTherapeutics.
Who are some of Stealth BioTherapeutics' key competitors?
Some companies that are related to Stealth BioTherapeutics include Dicerna Pharmaceuticals (DRNA), AnaptysBio (ANAB), TherapeuticsMD (TXMD), Amphastar Pharmaceuticals (AMPH), Epizyme (EPZM), Odonate Therapeutics (ODT), Athenex (ATNX), Y-mAbs Therapeutics (YMAB), Amneal Pharmaceuticals (AMRX), ANI Pharmaceuticals (ANIP), Phibro Animal Health (PAHC), G1 Therapeutics (GTHX), Eagle Pharmaceuticals (EGRX), Spectrum Pharmaceuticals (SPPI) and Dova Pharmaceuticals (DOVA).
What other stocks do shareholders of Stealth BioTherapeutics own?
Who are Stealth BioTherapeutics' key executives?
Stealth BioTherapeutics' management team includes the folowing people:
- Ms. Irene P. McCarthy J.D., Pres ,CEO, Sec. & Director (Age 54)
- Mr. Daniel E. Geffken, Interim Chief Financial Officer (Age 62)
- Mr. Mark J. Bamberger, Chief Scientific Officer (Age 66)
- Mr. Henry Hess, Chief Legal Counsel
- Dr. Ben R. Bronstein, Chief Medical Officer (Age 69)
When did Stealth BioTherapeutics IPO?
(MITO) raised $81 million in an IPO on Friday, February 15th 2019. The company issued 6,200,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets acted as the underwriters for the IPO and Nomura was co-manager.
When did the company's lock-up period expire?
Stealth BioTherapeutics' lock-up period expired on Wednesday, August 14th. Stealth BioTherapeutics had issued 6,500,000 shares in its public offering on February 15th. The total size of the offering was $78,000,000 based on an initial share price of $12.00. Since the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.
How do I buy shares of Stealth BioTherapeutics?
Shares of MITO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Stealth BioTherapeutics' stock price today?
One share of MITO stock can currently be purchased for approximately $7.15.
How big of a company is Stealth BioTherapeutics?
Stealth BioTherapeutics has a market capitalization of $250.46 million. The company earns $-96,710,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Stealth BioTherapeutics employs 57 workers across the globe.View Additional Information About Stealth BioTherapeutics.
What is Stealth BioTherapeutics' official website?
How can I contact Stealth BioTherapeutics?
Stealth BioTherapeutics' mailing address is 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466. The company can be reached via phone at 617-600-6888 or via email at [email protected]
MarketBeat Community Rating for Stealth BioTherapeutics (NASDAQ MITO)
MarketBeat's community ratings are surveys of what our community members think about Stealth BioTherapeutics and other stocks. Vote "Outperform" if you believe MITO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MITO will underperform the S&P 500 over the long term. You may vote once every thirty days.
